Federated Learning in Healthcare Market Report Scope & Overview:

The Federated Learning in Healthcare Market was valued at USD 30.85 Million in 2025 and is expected to reach USD 140.30 Million by 2035, growing at a CAGR of 16.35% from 2026-2035.

Federated learning in healthcare is a distributed machine learning approach that lets hospitals, research institutions and pharmaceutical sponsors train shared artificial intelligence models without moving identifiable patient records outside each institution's own governance boundary. Health systems are adopting this architecture as data protection authorities tighten cross-border transfer rules and as multi-site clinical research increasingly needs pooled statistical power without centralized data custody. Capital is following this shift, with specialized federated computing vendors attracting venture funding and large pharmaceutical sponsors licensing federated platforms to accelerate oncology and biologics research programs. On-premise deployments anchored to hospital-controlled infrastructure account for most production use today, while cloud-based federated orchestration is gaining acceptance as national health data platforms mature.

⮞Rhino Federated Computing disclosed on May 5, 2026, its selection to the CB Insights AI 100 list of private AI companies, citing federated infrastructure that supports Eli Lilly's TuneLab, the FAITE Consortium and the Cancer AI Alliance. Recognition of this kind signals that federated platforms are moving from research pilots into recurring infrastructure for pharmaceutical consortia and cancer research networks.

U.S. Federated Learning in Healthcare Market Outlook

The U.S. Federated Learning in Healthcare Market was valued at USD 9.58 Million in 2025 and is expected to reach USD 44.43 Million by 2035, growing at a CAGR of 16.60% from 2026-2035.

The U.S. market benefits from a concentrated base of academic cancer centers, federal research funders and specialized federated computing vendors that have moved federated learning from pilot projects into recurring research infrastructure. National Cancer Institute-affiliated consortia coordinate federated model validation across multiple cancer centers, giving U.S. institutions an early lead in applying the approach to oncology diagnostics. Venture investors have funded several U.S.-based federated computing vendors serving hospital systems and biopharmaceutical sponsors seeking compliant alternatives to centralized data pooling. Data governance requirements under federal and state health privacy law continue to shape how these platforms are deployed. Even so, sustained research funding and growing sponsor interest in federated trial infrastructure are expected to support steady U.S. market growth through 2035.

⮞Fred Hutchinson Cancer Center reported on March 4, 2026, that the Cancer AI Alliance, which receives technical and financial support from Google, Microsoft and NVIDIA among others, is road-testing eight federated pilot projects across its four member cancer centers, with models trained locally at each center and only the model shared. Pilots of this kind are expected to shorten the path from research model development to validated multi-center use across U.S. cancer centers.

By Application, Drug Discovery and Development Dominates the Federated Learning in Healthcare Market and Remote Patient Monitoring Grows Fastest

Drug Discovery and Development holds the largest application share because pharmaceutical sponsors increasingly license federated platforms to pool biologic and clinical trial data across research sites without transferring proprietary records to a single custodian. Licensing deals between federated AI vendors and large pharmaceutical companies have moved this application from exploratory pilots into recurring drug development infrastructure, particularly for oncology and biologics programs that depend on statistical power drawn from multiple sponsors. Regulatory acceptance of federated validation methods in drug development pipelines has reinforced sponsor confidence in committing budget to this application ahead of other federated learning use cases.

Remote Patient Monitoring is growing fastest because wearable and home-monitoring devices generate continuous patient data that health systems increasingly want to analyze jointly across institutions without transmitting identifiable records to a central server. Device makers and health systems are piloting federated frameworks that let monitoring algorithms improve using data distributed across multiple care settings rather than a single hospital's patient population. As chronic disease management programs expand the volume of remote monitoring data generated outside hospital walls, demand for federated analysis of this distributed data is expected to grow faster than the broader application mix through 2035.

⮞NVIDIA and Eli Lilly announced on January 12, 2026, a co-innovation AI lab for drug discovery in South San Francisco, backed by a reported USD 1 billion. Partnerships of this kind tie accelerated computing vendors directly to pharmaceutical sponsors, extending collaborative model development further into early-stage drug discovery workflows that have historically relied on centralized data-sharing agreements.

By Deployment Mode, On-premise Dominates the Federated Learning in Healthcare Market and Cloud-based Grows Fastest

On-premise deployment holds the largest share because hospitals and research institutions generally prefer to keep federated learning infrastructure inside their own data centers, where existing security controls and institutional review processes already govern patient data access. Health systems with established clinical data warehouses have been able to add federated model training capability on top of infrastructure they already operate, avoiding the additional vendor risk assessment that a new cloud platform would require. This preference for institution-controlled infrastructure keeps on-premise deployment ahead of cloud-based alternatives across the largest hospital systems and academic medical centers.

Cloud-based deployment is growing fastest as national health data platforms and smaller research institutions adopt managed federated learning services rather than building and maintaining their own infrastructure. Government-backed data platforms are increasingly hosted on cloud infrastructure that participating hospitals connect to without operating servers themselves, lowering the technical barrier for smaller trusts and institutions to join federated research networks. As more national and regional health data platforms mature on cloud infrastructure, cloud-based federated learning is expected to grow faster than on-premise deployment through 2035.

⮞Flower Labs and Aridhia disclosed on March 4, 2026, that Aridhia's Digital Research Environment can now host Flower federated learning nodes inside partner hospitals' secure workspaces, with the companies reporting that time to a first federated run can fall from about eight months to about one week. Managed environments of this kind show how cloud-hosted federated infrastructure can extend multi-site study participation to institutions that would otherwise lack the computing resources to join on their own.

By End-use, Hospitals and Healthcare Providers Dominates the Federated Learning in Healthcare Market and Pharmaceutical and Biotechnology Companies Grows Fastest

Hospitals and Healthcare Providers account for the largest end-use share because they generate and control the clinical data that most federated learning applications are designed to analyze, from diagnostic imaging to electronic health records. Large hospital systems and academic medical centers have become the anchor participants in most federated research networks, since federated model training requires institutions that already hold substantial patient data volumes and the governance infrastructure to participate responsibly. This position as both data source and primary beneficiary keeps hospitals and healthcare providers ahead of other end-use categories in federated learning adoption.

Pharmaceutical and Biotechnology Companies are the fastest-growing end-use category as drug sponsors increasingly license federated platforms to pool clinical trial and biologic data across research partners without centralizing proprietary records. Licensing agreements between pharmaceutical sponsors and federated AI vendors have expanded beyond early pilot programs into recurring drug development budgets, particularly for oncology and biologics research that benefits from pooled statistical power across multiple companies. As more sponsors adopt federated collaboration models for early-stage drug development, this end-use category is expected to grow faster than the broader end-use mix through 2035.

⮞Mayo Clinic Platform disclosed on February 20, 2026, plans to expand its governed health data and AI collaboration ecosystem in the United Arab Emirates and Saudi Arabia, deploying Orchestrate for managing AI tools from multiple vendors and Insights for population-level analysis. Platforms of this kind give health systems a structured path to join collaborative AI development without each institution building its own partnership network.

By Component, Software and Platforms Dominates the Federated Learning in Healthcare Market and Services Grows Fastest

Software and Platforms account for the largest component share because federated learning adoption depends on specialized orchestration software that coordinates model training across institutions while enforcing each participant's data governance requirements. Vendors offering federated computing platforms have captured most committed technology budget in this market, since hospitals and pharmaceutical sponsors typically license a platform rather than build federated infrastructure internally. Established platform vendors with healthcare-specific compliance features maintain the broadest customer base, reinforcing software and platforms as the dominant specification among institutions adopting federated learning.

Services are growing fastest as hospitals and research institutions increasingly need integration, validation and regulatory support to deploy federated learning platforms within their existing clinical data environments. Independent brokers and consulting firms are stepping in to coordinate multi-party federated projects, managing legal, project management and scientific support work that participating institutions cannot easily absorb internally. As more institutions move from pilot federated projects into recurring research infrastructure, demand for this supporting services layer is expected to grow faster than platform licensing alone through 2035.

⮞Apheris and T-Systems disclosed on October 20, 2026, that customers can run Apheris's federated data networks for drug research and real-world care data on T-Systems' sovereign T Cloud Public infrastructure, using NVIDIA GPUs and the NVIDIA FLARE framework. Managed offerings of this kind illustrate how specialized federated services providers are coordinating multi-party data collaboration that platform software alone cannot deliver.

Regional Analysis

North America Federated Learning in Healthcare Market Insights

With a share of 35.10% in 2025, North America led the market. The United States anchors regional demand through its concentration of academic cancer centers, federally funded research networks and specialized federated computing vendors, while Canada contributes through university-affiliated health research institutions exploring federated collaboration models. A deep base of venture capital and clinical research funding allows U.S.-based federated computing vendors to scale from pilot deployments into recurring institutional contracts. Established partnerships between U.S. cancer centers and federal research funders reinforce North America's position as both the leading adopter and the leading source of federated learning validation infrastructure for healthcare.

Sustained federal research funding for multi-institutional cancer research networks continues to expand the number of federated learning projects moving from pilot to production across the region. Growing sponsor interest in federated clinical trial infrastructure is adding new sources of demand beyond academic cancer research alone. Fragmented state and federal health privacy requirements can complicate how federated platforms are deployed across institutions in different jurisdictions. Taken together, the region's research funding depth, concentration of cancer research networks and growing pharmaceutical sponsor interest keep North America ahead of other regions in both demand and platform deployment.

⮞NVIDIA's FLARE Day 2026, held online from September 15 to September 24, 2026, included sessions from the Cancer AI Alliance, the National Cancer Institute's FLAIMME consortium, Mayo Clinic Platform and Eli Lilly's TuneLab on federated deployments across U.S. institutions. Programs of this kind show U.S. cancer centers and pharmaceutical sponsors extending federated validation methods beyond single-institution research programs.

Asia Pacific Federated Learning in Healthcare Market Insights

Asia Pacific is the second-largest regional market, with notable activity concentrated in China, Japan, India, South Korea and Taiwan. China anchors regional demand through its large hospital networks and growing national health technology investment, while Taiwan has moved further than most markets toward a coordinated national hospital federated learning strategy. Japan and South Korea contribute through established academic medical center research programs exploring federated collaboration for diagnostic imaging. Government support for national health data governance frameworks across several regional markets is gradually building the institutional trust needed for hospitals to participate in federated research networks.

Rising government investment in national health data governance frameworks is expanding the number of hospitals able to participate in federated research networks across the region. Growing academic medical center interest in diagnostic imaging and vital-sign prediction research is adding new sources of federated learning demand beyond cancer research alone. Fragmented data protection regulation across individual countries can complicate cross-border federated collaboration between regional research institutions. Despite these hurdles, coordinated national strategies in markets such as Taiwan and growing hospital network investment keep Asia Pacific as the fastest-growing region for federated learning in healthcare through 2035.

⮞Taiwan's Ministry of Health and Welfare announced in January 2026 an International High-Computing and Federated Learning Center, building on a pilot with 16 major hospitals and targeting expansion to 100 regional hospitals, with a planned Taiwan-Thailand collaboration through Mahidol University. Strategies of this kind give Asia Pacific health systems a structured path to scale federated learning beyond individual hospital pilot projects.

Europe Federated Learning in Healthcare Market Insights

Europe is the third-largest regional market, with notable demand concentrated in Germany, the Netherlands, France and the United Kingdom. Germany anchors regional demand through its hospital network research programs, while the Netherlands hosts academic medical centers advancing federated genomic research methods. The United Kingdom's national health system has built one of the most extensive government-backed federated data platforms in the region, connecting a large and growing number of hospital trusts. Regional data protection regulation, including the European Union's health data governance framework, is shaping how federated platforms handle cross-border research collaboration.

Coordinated European Union health data governance rules are expanding the legal basis for federated research collaboration across member states without requiring hospitals to centralize patient records. The United Kingdom's national federated data platform continues to add hospital trusts and integrated care boards, broadening the installed base of institutions capable of joining multi-site federated research. Variation in how individual member states implement shared data governance rules can lengthen the time needed to launch new cross-border federated projects. Against these constraints, sustained regulatory coordination and continued National Health Service platform expansion support steady growth for federated learning in healthcare across European markets through 2035.

⮞Owkin and Université Paris-Saclay signed a memorandum of understanding on November 20, 2025, to make Owkin's K Pro Free AI co-pilot for biology available across the university's biomedical research community. Agreements of this kind give European academic institutions a route into patient-data-trained AI tools without building their own platforms.

MEA & Latin America Federated Learning in Healthcare Market Insights

The Middle East and Africa region remains an early-stage market for federated learning in healthcare, with Saudi Arabia and the United Arab Emirates leading regional activity through national digital health investment programs, while South Africa and several African research institutions are piloting federated methods in resource-constrained clinical settings. International federated computing vendors are beginning to explore partnerships with regional health systems as government-backed digital health strategies create early demand for collaborative AI research. Limited local computing infrastructure and a smaller base of specialized federated learning engineers keep regional adoption concentrated in pilot research projects rather than production deployment.

Latin America adds demand through growing hospital network digitization, with Brazil leading regional activity followed by Mexico, Argentina and Colombia. Public health systems across Brazil and Mexico are exploring federated approaches to pool diagnostic imaging data across multiple hospitals without centralizing patient records in a single national database. Local federated computing expertise remains limited across the region, and inconsistent health data protection regulation between countries complicates long-term platform planning for international vendors. On balance, expanding hospital digitization and growing government interest in collaborative health AI support a gradual increase in regional federated learning adoption through 2035.

⮞Mayo Clinic and Einstein Hospital Israelita reported on August 3, 2026, that Einstein's de-identified clinical data is now available through Mayo Clinic Platform_Connect, a network of eight members across seven countries, including Aga Khan University in Kenya, in which institutions keep control of their own records. Arrangements of this kind point to growing participation by hospitals in Latin America and Africa in privacy-preserving global AI networks, though adoption remains concentrated among a small number of leading institutions.

Market Dynamics

Growth Drivers: Expanding data privacy regulation and pharmaceutical licensing demand are driving adoption

Tightening data protection and cross-border transfer rules are pushing hospitals, research institutions and pharmaceutical sponsors toward federated learning as a way to train shared AI models without moving identifiable patient records outside each institution's own jurisdiction. Regulators across major healthcare markets are increasingly treating data residency as a compliance requirement rather than a preference, which gives federated architectures a structural advantage over centralized data pooling for any new multi-site research program. Growing government investment in national health data platforms reinforces this shift, as health systems build federated infrastructure to support population-level analytics without centralizing records nationally.

A second driver is the growing willingness of pharmaceutical sponsors to license federated platforms for drug discovery and clinical trial collaboration, since pooling biologic and trial data across companies and research sites can improve model performance beyond what any single sponsor's dataset would support alone. Independent brokers are stepping in to coordinate these multi-party arrangements, managing the legal and scientific work needed to let competing companies collaborate without disclosing proprietary data. This growing comfort with structured multi-party collaboration is extending federated learning from academic cancer research into mainstream pharmaceutical research budgets.

⮞Owkin disclosed on May 12, 2026, a three-year K Pro license agreement with AstraZeneca under which it will build AI agents integrated into the pharmaceutical company's decision workflows. Agreements of this kind show pharmaceutical sponsors moving from pilot projects to multi-year platform licenses with specialized AI and data vendors.

Restraints: Regulatory fragmentation and limited federated learning expertise slow broader deployment

Federated learning deployments must satisfy data protection and research ethics requirements that differ across countries and even across individual hospital systems, which complicates the design of a single federated platform that can serve institutions in multiple jurisdictions at once. This fragmentation can slow the pace at which multi-site research networks expand beyond their founding institutions, since each new participant typically requires its own legal and compliance review before joining. Smaller hospitals and research institutions without dedicated data governance staff are particularly exposed to this administrative burden when evaluating whether to join a federated research network.

A shortage of engineers and data scientists experienced in federated learning infrastructure also limits how quickly hospitals and pharmaceutical sponsors can move from pilot projects to production deployment. Specialized federated computing vendors and independent brokers are partially filling this gap, but demand for this expertise still outpaces the available talent pool across most healthcare markets. Institutions that lack in-house federated learning expertise often depend entirely on external vendors to design and maintain their federated infrastructure, which can slow internal adoption and raise long-term platform costs.

⮞The European Commission presented its Digital Omnibus package on November 19, 2025, proposing changes to the General Data Protection Regulation that would, among other measures, empower the Commission to specify when pseudonymised data counts as personal data and treat scientific research as a legitimate interest. Proposals of this kind, still subject to approval by the European Parliament and Council, leave federated learning vendors planning around evolving rather than settled compliance requirements across European countries.

Opportunities: Open federated frameworks and wearable data integration are widening the addressable market

Open-source federated learning frameworks are lowering the barrier for smaller hospitals and research institutions to join collaborative model training without committing to a single proprietary vendor's platform. Technology companies distributing these frameworks are also publishing healthcare-specific reference architectures that reduce the engineering effort needed to connect a new institution to an existing federated research network. This growing availability of accessible frameworks gives smaller health systems in lower-resource markets a more practical path to participate in federated research than the custom infrastructure that early projects required.

Expanding wearable and remote monitoring device adoption is also creating a new category of distributed health data that federated learning is well suited to analyze without centralizing device-level patient data on a single server. Researchers are already developing privacy-preserving frameworks specifically for wearable and stress-monitoring data that could extend federated learning beyond hospital and clinical trial settings into continuous, at-home patient monitoring. As wearable device adoption continues to expand across chronic disease management programs, this distributed data source is expected to create a meaningfully larger addressable market for federated learning platforms through 2035.

⮞Owkin disclosed on January 12, 2026, the launch of Pathology Explorer, an AI agent trained on histopathology data from more than 800 hospitals across 104 healthcare centers and accessible through the Model Context Protocol, including through Anthropic's Claude for Healthcare and Life Sciences. Interface-based offerings of this kind point to patient-data-trained models reaching a wider range of healthcare and life sciences users beyond hospital and clinical trial infrastructure.

Federated Learning in Healthcare Market Key Players

• FedML, Inc.

• Google LLC

• NVIDIA Corporation

• Owkin, Inc.

• Rhino Federated Computing, Inc.

• Apheris AI GmbH

• International Business Machines Corporation

• Flower Labs GmbH

• Duality Technologies, Inc.

Federated Learning in Healthcare Market Report Scope: